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The relationship between P-gp and CD147 in the regulation of MDR in leukemic cells has not been re-
ported. This study aimed to investigate the correlation between CD147 and P-gp in the regulation of drug
resistance in the K562/ADR leukemic cell line. The results showed that drug-resistant K562/ADR cells
expressed signiﬁcantly higher P-gp and CD147 levels than drug-free K562/ADR cells. To determine the
regulatory effect of CD147 on P-gp expression, anti-CD147 antibody MEM-M6/6 signiﬁcantly decreased
P-gp and CD147 mRNA and protein levels. This is the ﬁrst report to show that CD147 mediates MDR in
leukemia through the regulation of P-gp expression.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Leukemia, a type of blood cancer, originates from abnormal
hematopoietic stem cells and results in a high number of abnormal
white blood cells. Chemotherapy, using cytotoxic drugs to destroy
cancer cells, has been the most effective treatment. However,
multidrug resistance (MDR), the ability of cancer cells to survive
exposure to many chemotherapeutic drugs, is the major problem
in cancer treatment. Recent studies have revealed that over-
expression of drug transporter proteins, such as P-glycoprotein (P-
gp), is associated with resistance to multiple chemotherapeutic
drugs [1,2]. P-gp is a 170 kDa transmembrane protein encoded by
the MDR1 gene. It functions as a pump to remove anticancer drugs
from cells, thereby leading to drug resistance. As reported, P-gp is
overexpressed in several drug-resistant cancer cell lines [3–5].
Thus, P-gp might potentially be a key molecule in MDR cancer.
However, the regulatory mechanism of this protein was not elu-
cidated. CD147 is a protein in the immunoglobulin superfamily
group [6–9]; it promotes many properties of cancer cells, including
multidrug resistance [10–12]. A number of studies have shown the
high expression level and involvement of CD147 in many MDR cellLtd. This is an open access article u
oscopy, Department of Med-
ces, Chiang Mai University,
hiampanichayakul).lines [13,14]. These studies suggested that CD147 plays an im-
portant role in regulating resistance to anticancer drugs. However,
the regulatory mechanism of CD147 on the P-gp in leukemic cells
remains unclear.
In this study, drug-free K562/ADR cells were established and
then used as a drug-resistant phenotype cell control. The CD147
and P-gp demonstrated high expression in drug-resistant K562/
ADR cells more than drug-free K562/ADR cells, in both mRNA and
protein levels. In addition, the mechanism through which CD147
regulates P-gp in multidrug-resistant leukemic cells was in-
vestigated using monoclonal antibodies (mAb) against CD147,
MEM-M6/6. MEM-M6/6 down-regulated the expression of MDR1
mRNA and P-gp in drug-resistant K562/ADR cells. The CD147 was
purposed to involve in multidrug resistance through regulation of
P-gp expression in leukemia cells.2. Materials and methods
2.1. Antibodies
This study used the following antibodies: mouse anti-CD147
monoclonal antibody clone MEM-M6/6 (Exbio, Vestec, Czech Re-
public); mouse anti-P-gp monoclonal antibody (MT PGP1) (Bio-
medical Technology Research Center, Chiang Mai, Thailand) [15],
mouse anti-γ4 globin monoclonal antibody (PB1) (Biomedicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
The sequences of primers used to amplify MDR1, BSG, BIRC5 and GAPDH mRNAs
[3,17].
Gene Primer sequence
MDR1 Sense 5′-AAAGCGACTGAATGTTCAGTGG-3′
Antizense 5′-AATAGATGCCTTTCTGTGCCAG-3′
BSG Sense 5′-GCAGCGGTTGGAGGTTGT-3′
Antizense 5′-AGCCACGATGCCCAGGAAAGG-3′
BIRC5 Sense 5′-TGGCTGCCATGGATTGAG-3′
Antizense 5′-TCTGAGGAGGCACAGGTGT-3′
GAPDH Sense 5′-CAACGTGTCAGTGGTGGACCTG-3′
Antizense 5′-TTACTCCTTGGAGGCCATGTGG-3′
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Fig. 1. Cytotoxicity of Adriamycin on drug-resistant K562/ADR and drug-free K562/
ADR leukemia cell lines by MTT assay. Cells were treated with Adriamycin drug (0–
10 μM) for 48 h. and the cytotoxicity was measured by the MTT assay. Data re-
present as mean7SEM of three independent experiments; npo0.05 when com-
pared to drug-free K562/ADR cell.
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antibody (Abcam, Cambridge, UK), rabbit anti-GAPDH polyclonal
antibody (Merck Millipore, Billeric, MA, USA), goat anti-rabbit IgG-
HRP (Abcam), and rabbit anti-mouse Igs-FITC (Dako, Hamburg,
Germany).
2.2. Cell lines and culture
The human leukemia cell line, K562/ADR (Adriamycin resistant
K562) was purchased from Riken (Riken, Yokohama, Japan) and
maintained in RPMI1640 medium (GIBCO™, Grand Island, NY,
USA) supplemented with 10% fetal bovine serum (FBS), penicillin,
and streptomycin at 37 °C in 5% CO2. Before the experiment, the
drug-resistant K562/ADR was cultured in 0.5, 0.75, and 1 μg/mL of
Adriamycin (Sigma, St. Louis, MO, USA) to maintain MDR pheno-
type. Drug-free K562/ADR was generated by growing K562/ADR in
culture mediumwithout Adriamycin for at least 5 months to make
them sensitive to Adriamycin.
2.3. Antibody treatment
To determine the involvement of the CD147 molecule on the
expression and function of P-gp, drug-resistant K562/ADR cells
were plated at 2105 cells/well, then co-cultured with anti-CD147
clone MEM-M6/6 (Exbio) at various concentrations (0–5 mg/mL)
for 24–48 h. PB1 antibody against γ4-globin (hemoglobin Bart's)
was used as the isotype matched control (IgG1).
2.4. Western blot analysis
Cells were harvested and extracted with RIPA lysis buffer. The
total protein concentration was determined using the Folin-Lowry
method and 30 μg of total protein were electrophoresed on 10%
SDS-PAGE gels. After electrophoresis, the proteins were trans-
ferred to polyvinylidene diﬂuoride membranes. The blots were
blocked with 5% skim milk-PBS before incubating with 10 μg/mL
of mouse monoclonal anti-P-gp antibody (MT-PGP1) (Biomedical
Technology Research Center), 1 μg/mL of rabbit polyclonal anti-
CD147 antibody (Abcam), or 1 μg/mL of rabbit polyclonal anti-
GAPDH antibody (Merck Millipore) for 1 h. Then goat polyclonal
anti-rabbit IgG conjugated with HRP (1:20,000 dilution; Abcam) or
polyclonal rabbit anti-mouse IgG-HRP (1:5000 dilution; Dako) was
added for 2 h. After washing, the signal was detected using Lu-
minata™ forte Western HRP Substrate (Merck Millipore).
2.5. Semi-quantitative reverse transcription-PCR
Total RNA was extracted from cells with TRIzol reagent (Life
Technologies) according to the manufacturer's instructions. Single-
stranded cDNAwas synthesized by reverse transcription from 1 μg
of total RNA using the RevertAid strand cDNA Synthesis Kit
(Thermo Scientiﬁc, USA). Then, 1 μg cDNA was ampliﬁed by PCR
using a DreamTag Green PCR Master Mix (Thermo ScientiﬁcTM).
The primer sequences are shown in Table 1. The PCR products
were electrophoresed on 1.2% agarose gels, followed by ethidium
bromide staining.
2.6. Intracellular rhodamine 123 (Rho123) accumulation assay
After treatment, 2105 cells were incubated with Rho123 dye
at a ﬁnal concentration of 10 μM for 90 min. After incubation, the
cells were harvested and washed twice with ice-cold PBS, and
then resuspended in PBS. The ﬂuorescence intensity of the cells
was determined using a FACS Calibur ﬂow cytometer (Becton
Dickinson, San Jose, CA, USA).2.7. Statistical analysis
Data were expressed as mean7SEM. Statistical analysis was
performed with SPSS 20.0 software. Statistical signiﬁcance be-
tween two groups was determined by Student's t-test. Results
from more than two experimental groups were evaluated by one-
way Mann-Whitney U test. A difference was considered statisti-
cally signiﬁcant at po0.05.3. Results
3.1. Expression of P-gp and CD147 in drug-resistant and drug-free
K562/ADR leukemic cell lines
To investigate the multidrug resistance phenotype of drug-re-
sistant K562/ADR and drug-free K562/ADR cell lines, MTT assay
was performed to compare the sensitivity of both leukemia cell
lines to Adriamycin drug. Drug-resistant K562/ADR and drug-free
K562/ADR cell lines were treated with various concentrations of
Adriamycin for 48 h. It was found that Adriamycin was more cy-
totoxic effect to drug-free K562/ADR than drug-resistant K562/
ADR cells (Fig. 1). Western blot analysis and semi-quantitative RT-
PCR were employed to determine the expression levels of P-gp and
CD147 in both drug-resistant K562/ADR and drug-free K562/ADR
cells. Representative samples of the immunoblotting results are
shown in Fig. 2A. The results showed a higher expression level of
P-gp and CD147 proteins in drug-resistant K562/ADR than in drug-
free K562/ADR (po0.05) (Fig. 2B). Furthermore, the results
showed signiﬁcantly higher expression levels of MDR1 and
BSG mRNA in drug-resistant K562/ADR compared to drug-free
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Fig. 2. The protein expressions of P-gp and CD147 in drug-resistant K562/ADR and drug-free K562/ADR leukemic cell lines. Proteins were extracted drug-resistant K562/ADR
and drug-free K562/ADR cell lines and separated by 12% SDS-PAGE and transferred onto PVDF membrane. The membranes were probed with anti-CD147, anti-P-gp and
detected by enhanced chemiluminescence. (A) Results are representative of three independent experiments by Western blotting and (B) Quantiﬁcation of P-gp and CD147
expressions in drug-resistant K562/ADR and drug-free K562/ADR cells; the protein levels were normalized to the loading control GAPDH. The ratio of P-gp and CD147 were
calculated for each group. Data are presented as mean7SEM of three independent experiments; npo0.05 when compared to drug-free K562/ADR cell.
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Fig. 3. The level of MDR1 and BSG mRNA in drug-resistant K562/ADR and drug-free K562/ADR leukemic cell lines. Total RNA was extracted from cells and the reverse
transcription reaction were performed using a RevertAid First Strand cDNA Synthesis kit (Thermo Scientiﬁc™). The newly synthesized cDNA was ampliﬁed by PCR using
speciﬁc primers. The PCR product were electrophoresed on 1.2% agarose gel and visualized by ethidium bromide staining. (A) Results are representative of three independent
experiments by semiquantitative RT-PCR analysis and (B) quantiﬁcation of MDR1 (multidrug resistance 1) and BSG (Basigin) mRNA expression in drug-resistant K562/ADR
and drug-free K562/ADR cells; the mRNA levels were normalized to the loading control GAPDH. The ratio of MDR1 and BSG mRNAs were calculated for each group. Data are
presented as mean 7SEM of three independent experiments; npo0.05 when compared to drug-free K562/ADR cell.
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and CD147 levels were much higher in drug-resistant K562/ADR
than drug-free K562/ADR cells. According to the previous reports,
these results conﬁrmed that P-gp and CD147 were involved in the
leukemic cell with MDR phenotype.3.2. MEM-M6/6 mAb inhibits the expression of P-gp and CD147
protein in drug-resistant K562/ADR cell line
Because CD147 is involved in cancer multidrug resistance, the
CD147 was further determined in the regulation of P-gp. Drug-
resistant K562/ADR cells were treated with MEM-M6/6 anti-CD147 or PB1 anti-γ4 globin (isotype matched control) for 48 h,
then the expression of P-gp and CD147 proteins was examined by
Western blotting. As shown in Fig. 4, the results demonstrated that
MEM-M6/6 antibody treatment signiﬁcantly decreased the ex-
pression of P-gp and CD147 proteins in a dose-dependent manner.
The MEM-M6/6 mAb at 5 μg/mL had no effect on cell viability
(data not shown). In contrast, at 5 μg/mL, PB1 anti-γ4 globin mAb
showed no difference of all tested proteins expression.
3.3. MEM-M6/6 mAb inhibits the expression of MDR1 and BSG
mRNA in drug-resistant K562/ADR cells
The effects of MEM-M6/6 mAb on MDR1 and BSG mRNA
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Fig. 4. Effect of MEM-M6/6 anti-CD147 on P-gp (A) and CD147 (B) protein ex-
pression in drug-resistant K562/ADR cell line. The protein levels after treating
drug-resistant K562/ADR cell with (1) 0 μg/mL MEM-M6/6, (2) 0.625 μg/mL,
(3) 1.25 μg/mL, (4) 2.5 μg/mL, and (5) 5 μg/mL for 48 h were determined byWestern
blotting. The bands were quantiﬁed using a scan densitometer. The protein levels
were normalized to the loading control GAPDH. Data are presented as mean7SEM
of three independent experiments; npo0.05 when compared to untreated cell.
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Fig. 5. Effect of MEM-M6/6 anti-CD147 on MDR1 (A) and BSG (B) mRNA levels in
drug-resistant K562/ADR cell line. The quantiﬁcation of mRNA expression in the
presence of various concentrations of MEM-M6/6 (0–5 mg/mL) were normalized to
the loading control GAPDH mRNA. The ratio of mRNA was calculated for each
group. Data are presented as mean7SEM of three independent experiments;
npo0.05 when compared to untreated K562/ADR cell.
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Drug-resistant K562/ADR cells were cultured with MEM-M6/6
mAb for 24 h. The results showed that MEM-M6/6 decreased the
expression of MDR1 and BSG mRNA levels in drug-resistant K562/
ADR cells in a dose-dependent manner compared to untreated
cells (Fig. 5). In addition, 5 μg/mL MEM-M6/6 antibody sig-
niﬁcantly decreased MDR1 and BSG mRNA levels (po0.05). For
the isotype matched control, the results showed no difference in
the mRNA levels in treated and untreated drug-resistant K562/ADR cells. These results suggested that triggering CD147 by anti-
CD147 mAb MEM-M6/6 decreased the expression of CD147, lead-
ing to a decrease of MDR1 expression.
3.4. Effects of MEM-M6/6 mAb on P-gp function
To investigate whether MEM-M6/6 mAb affects P-gp function,
the intracellular accumulation of Rho123 in the presence or ab-
sence of MEM-M6/6 antibody was determined in drug-resistant
K562/ADR and drug-free K562/ADR cells. As shown in Fig. 6, the
relative mean ﬂuorescence intensity (MFI) in drug-resistant K562/
ADR cells was signiﬁcantly lower than drug-free K562/ADR cells
(po0.05). For drug-resistant K562/ADR cells, there was no sig-
niﬁcant difference in Rho123 intracellular accumulation in MEM-
M6/6 antibody treatment compared to untreated cells. The accu-
mulation of Rho123 did not alter in PB1 anti-γ4 globin mAb
treated cells. However, the MFI of Rho123 was signiﬁcantly higher
in curcumin (MDR modulator) treated K562/ADR cells than un-
treated cells (po0.05).
4. Discussion
There are several mechanisms of MDR, including decreased
Fig. 6. Effect of MEM-M6/6 on P-gp function by Rhodamine 123 accumulation assay. Drug-resistant K562/ADR cells were treated with MEM-M6/6 or curcumin for 48 h, then
Rho123 was added and incubated for further 90 min. Fluorescence intensity of Rho123 was analyzed by ﬂow cytometry. (A) Results are representative of intracellular Rho123
accumulation and (B) Relative mean ﬂuorescence intensity of various conditions. Results are presented as mean 7SEM of three independent experiments. npo0.05 when
compared to drug-free K562/ADR cell, #po0.05 when compared to untreated drug-resistant K562/ADR cell.
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pumps, or altered cell-cycle checkpoints [18–20]. Among these,
overexpression of P-gp, ATP-binding cassette (ABC) drug trans-
porters, is an important mechanism [1,2]. P-gp is a transmem-
brane glycoprotein that is widely expressed in many human can-
cers [21]. Levels of P-gp have been correlated with drug resistance
in several different cancers [1,2,20,22]. Therefore, understanding
MDR is important to help patients for reducing or preventing
chemotherapy resistance.
CD147 is a type I transmembrane glycoprotein of the im-
munoglobulin superfamily. CD147 has been reported to regulate
the expression of P-gp and affect apoptosis in cancer cells with
MDR phenotype [10,13,14]. In the present study, drug-free K562/ADR was ﬁrst established by culturing K562/ADR in medium
without Adriamycin for at least ﬁve months. Then Adriamycin
drug sensitivities of both drug-resistant and drug-free K562/ADR
cells were determined and compared by MTT assay. The results
showed that Adriamycin was more cytotoxic in drug-free K562/
ADR cells than drug-resistant K562/ADR cells. Moreover, the drug-
resistant K562/ADR cell line presented high expression levels of
P-gp and CD147, suggesting that both proteins are associated with
the MDR phenotype in leukemic cells. This ﬁnding is in line with
previous studies that have demonstrated high levels of mRNA and
protein expression of MDR1 and CD147 in MDR cancer cell lines
[13]. Recent studies have revealed CD147 is responsible for
the altered multidrug resistance to P-gp substrate drugs [14].
A. Somno et al. / Leukemia Research Reports 6 (2016) 33–3838Up-regulation of MDR1 at both transcription and expression levels
was found in CD147-transfected MCF7 breast cancer cells, which
promotes multidrug resistance to P-gp substrate drugs. In addi-
tion, silencing of CD147 led to increase chemosensitivity in MDR
cancer cell lines [23,24]. As previously mentioned, the linkage
exists among CD147 and P-gp in leukemia with MDR were further
investigated. Drug-resistant K562/ADR cells were co-cultured with
MEM-M6/6 anti-CD147 mAb, and then P-gp and CD147 expression
were determined by Western blotting and semi-quantitative RT-
PCR. The MEM-M6/6 antibody decreased the expression of P-gp
and CD147 proteins and mRNA levels, suggesting the regulation of
P-gp expression by CD147 molecule in the association of multidrug
resistant phenotype in K562/ADR cells. As previously reported, the
CD147 molecule contains different bioactive domains responsible
for cell functions [25]. Therefore, activation of bioactive domains,
by speciﬁc mAbs or its natural ligands, induces different cellular
responses [25]. MEM-M6/6 was reported as a CD147 mAb, which
recognized the membrane-proximal domain of the CD147 mole-
cule [26]. These results suggest that the membrane-proximal do-
main of the CD147 molecule may be a particular domain that is
responsible for the regulation of multidrug resistance. Further-
more, triggering CD147 with MEM-M6/6 decreased the expression
of CD147, which in turn down-regulated P-gp expression.
The further investigation was performed by using MEM-M6/6
antibody to observe the linkage exits between CD147 and P-gp
activity by intracellular Rho123 accumulation. MEM-M6/6 treat-
ment did not alter Rho123 accumulation in drug-resistant K562/
ADR cells. In contrast, the ﬂuorescence intensity of Rho123 was
signiﬁcantly high in K562/ADR cells treated with curcumin, which
is a P-gp modulator used as a positive control [27]. These results
indicated that the decreased expression of CD147 by anti-CD147
MEM-M6/6 did not affect the P-gp function. It has been suggested
that CD147 is involved in leukemia drug resistance by down-reg-
ulating Pgp, but not related to its drug efﬂux function [28,29].
Triggering of CD147 by MEM-M6/6 anti-CD147 mAb decreased
expression of CD147 and caused downregulation of P-gp, but had
no effect on P-gp function. Most strategies to reverse MDR phe-
notype in cancer cells have used drug efﬂux modulators. Moreover,
to avoid MDR could be downregulated the expression of the target
gene that involved in MDR such as MDR1 gene. Therefore, we
propose regulating CD147 expression as a new strategy to over-
come MDR. In summary, the CD147 involved the MDR phenotype
of leukemic cells by regulating P-gp expression.Acknowledgments
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